SE8406081D0 - Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration - Google Patents

Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration

Info

Publication number
SE8406081D0
SE8406081D0 SE8406081A SE8406081A SE8406081D0 SE 8406081 D0 SE8406081 D0 SE 8406081D0 SE 8406081 A SE8406081 A SE 8406081A SE 8406081 A SE8406081 A SE 8406081A SE 8406081 D0 SE8406081 D0 SE 8406081D0
Authority
SE
Sweden
Prior art keywords
composition
preparation
oral administration
controlled long
acting pharmaceuticals
Prior art date
Application number
SE8406081A
Other languages
English (en)
Other versions
SE8406081L (sv
SE461071B (sv
Inventor
Hans Lowey
Original Assignee
Hans Lowey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Lowey filed Critical Hans Lowey
Publication of SE8406081D0 publication Critical patent/SE8406081D0/sv
Publication of SE8406081L publication Critical patent/SE8406081L/sv
Publication of SE461071B publication Critical patent/SE461071B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8406081A 1983-12-01 1984-11-30 Farmaceutisk baerare innefattande hydroxipropylmetylcellulosa, hydroxipropylcellulosa och en karboxivinylpolymer samt ett komposition innefattande baeraren SE461071B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/556,844 US4680323A (en) 1983-12-01 1983-12-01 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration

Publications (3)

Publication Number Publication Date
SE8406081D0 true SE8406081D0 (sv) 1984-11-30
SE8406081L SE8406081L (sv) 1985-06-02
SE461071B SE461071B (sv) 1990-01-08

Family

ID=24223083

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8406081A SE461071B (sv) 1983-12-01 1984-11-30 Farmaceutisk baerare innefattande hydroxipropylmetylcellulosa, hydroxipropylcellulosa och en karboxivinylpolymer samt ett komposition innefattande baeraren

Country Status (26)

Country Link
US (1) US4680323A (sv)
JP (1) JPS60185728A (sv)
KR (1) KR930000046B1 (sv)
AT (1) AT394948B (sv)
AU (1) AU572571B2 (sv)
BE (1) BE901186A (sv)
CA (1) CA1229551A (sv)
CH (1) CH664970A5 (sv)
DE (1) DE3443587C2 (sv)
DK (1) DK162511C (sv)
EG (1) EG17134A (sv)
FI (1) FI82601C (sv)
FR (1) FR2555901B1 (sv)
GB (1) GB2152940B (sv)
HU (1) HU193717B (sv)
IE (1) IE58112B1 (sv)
IL (1) IL73594A (sv)
IT (1) IT1177152B (sv)
LU (1) LU85660A1 (sv)
MX (1) MX161165A (sv)
NL (1) NL193164C (sv)
NO (1) NO167002C (sv)
NZ (1) NZ210310A (sv)
PT (1) PT79427B (sv)
SE (1) SE461071B (sv)
ZA (1) ZA849373B (sv)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
IE59287B1 (en) * 1984-02-10 1994-02-09 Benzon Pharma As Diffusion coated multiple-units dosage form
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
EP0205336B1 (en) * 1985-06-11 1991-09-11 Teijin Limited Oral sustained release pharmaceutical preparation
JPS61286330A (ja) * 1985-06-11 1986-12-16 Teijin Ltd 経口徐放性製剤
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
US4783331A (en) * 1987-06-29 1988-11-08 Miles Inc. Method for solubilization of aspartame in effervescent aqueous systems; and composition
AU2252388A (en) * 1988-05-02 1989-11-29 Zila Pharmaceuticals Compositions and in situ methods for forming films on body tissue
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US5498422A (en) * 1991-04-08 1996-03-12 Nippon Shinyaku Company Limited Sustained release capsule
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
NO924985L (no) * 1991-12-30 1993-07-01 Akzo Nv Thyroaktiv blanding med vedvarende frigjoering
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
DK0906089T3 (da) * 1996-05-13 2003-12-08 Novartis Consumer Health Sa Mundafgivelsessystem
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US6479082B1 (en) 1996-12-23 2002-11-12 Wm. Wrigley, Jr. Co. Process of increasing flavor release from chewing gum using hydroxypropyl cellulose and product thereof
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
PL340456A1 (en) * 1997-11-12 2001-02-12 Boehringer Mannheim Pharm Corp Novel oral dosage form of carvedilol
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
WO2000037081A1 (en) * 1998-12-22 2000-06-29 Novo Nordisk A/S Novel formulation
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000059314A1 (en) 1999-04-01 2000-10-12 Wm. Wrigley Jr. Company Long flavor duration releasing structures for chewing gum
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US20060147530A1 (en) * 2002-10-22 2006-07-06 Viswanathan Narayanan B Sustained release compositions containing alfuzosin
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20080318311A1 (en) 2004-11-02 2008-12-25 Gangagen Life Sciences Inc. Encapsulated Bacteriophage Formulation
AU2006282506A1 (en) * 2005-08-23 2007-03-01 Nissan Chemical Industries, Ltd. Sustained-release preparation
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
AU2008210327B2 (en) * 2007-01-31 2011-06-16 Methylation Sciences International Srl Extended release pharmaceutical formulations of S-adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
KR100836960B1 (ko) * 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009143072A1 (en) * 2008-05-19 2009-11-26 Wynden Pharmaceuticals, Inc. High-loading, controlled-release magnesium oral dosage forms and methods of making and using same
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
CN115429815B (zh) * 2021-06-02 2023-12-22 广州帝奇医药技术有限公司 一种长效饱腹组合物、制备方法及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3138524A (en) * 1962-06-06 1964-06-23 Hoffmann La Roche Pharmaceutical suspensions
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
US3590117A (en) * 1969-03-24 1971-06-29 Richardson Merrell Inc Long-lasting troche containing guar gum
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
CA945899A (en) * 1971-09-16 1974-04-23 Hans Lowey Long-acting oral carrier
CA1018456A (en) * 1972-06-26 1977-10-04 Hans Lowey Prolonged release lozenges
US3876771A (en) * 1973-09-04 1975-04-08 Hallister Inc Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS55118414A (en) * 1979-03-05 1980-09-11 Teijin Ltd Prolonged release drug and its preparation
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS58192817A (ja) * 1982-05-06 1983-11-10 Nippon Soda Co Ltd 棒状製剤の製造方法
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
IL73594A (en) 1988-12-30
SE8406081L (sv) 1985-06-02
US4680323A (en) 1987-07-14
FI82601C (sv) 1991-04-10
IL73594A0 (en) 1985-02-28
BE901186A (fr) 1985-03-15
DK569784A (da) 1985-06-02
HU193717B (en) 1987-11-30
GB2152940B (en) 1987-09-03
DE3443587C2 (de) 1986-11-06
PT79427A (en) 1984-11-01
LU85660A1 (de) 1985-06-04
IE843077L (en) 1985-06-01
KR930000046B1 (ko) 1993-01-06
NL8403522A (nl) 1985-07-01
MX161165A (es) 1990-08-09
DE3443587A1 (de) 1985-06-27
NL193164B (nl) 1998-09-01
PT79427B (en) 1986-09-15
DK162511B (da) 1991-11-11
NO844280L (no) 1985-06-03
NO167002C (no) 1991-09-25
IT1177152B (it) 1987-08-26
HUT35531A (en) 1985-07-29
AT394948B (de) 1992-07-27
CA1229551A (en) 1987-11-24
KR850004392A (ko) 1985-07-15
AU3449984A (en) 1985-06-06
IT8423523A1 (it) 1986-05-09
DK569784D0 (da) 1984-11-30
GB8430083D0 (en) 1985-01-09
GB2152940A (en) 1985-08-14
ATA382484A (de) 1992-01-15
DK162511C (da) 1992-03-30
FI844656L (fi) 1985-06-02
NZ210310A (en) 1988-01-08
FI82601B (fi) 1990-12-31
IT8423523A0 (it) 1984-11-09
CH664970A5 (de) 1988-04-15
SE461071B (sv) 1990-01-08
NL193164C (nl) 1999-01-05
NO167002B (no) 1991-06-17
ZA849373B (en) 1985-07-31
FR2555901A1 (fr) 1985-06-07
AU572571B2 (en) 1988-05-12
EG17134A (en) 1991-08-30
FR2555901B1 (fr) 1988-06-10
JPS60185728A (ja) 1985-09-21
IE58112B1 (en) 1993-07-14
FI844656A0 (fi) 1984-11-27

Similar Documents

Publication Publication Date Title
SE8406081D0 (sv) Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
SE8702907D0 (sv) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
FI872864A0 (sv) Förfarande för framställning av farmaceutiskt aktiva bensimidazolföreningar
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
ES8608864A1 (es) Un procedimiento para producir un preparado a modo de hojas
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
NO168628C (no) Fremgangsmaate for fremstilling av perorale preparater inneholdende antidiabetiske sulfonylurea-forbindelser og/eller benzosyrederivater
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
IT8620846A0 (it) Derivati di acido valproico e di acido (e)-2-valproenoico, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
NO870560D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
LV10949A (lv) Aizvietoti 4-fenil-4piperidinkarboksamidi to iegusanas panemiens farmaceitiska kompozicija
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
DE3764111D1 (de) Arzneimittelkombination.
IT1196958B (it) Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche
SE8004383L (sv) Farmaceutisk beredning for oral administrering och forfarande for dess framstellning
IL82925A0 (en) Tetrahydrobenzothiazoles,their preparation and pharmaceutical compositions containing them
EP0218953A3 (en) Derivatives of 19,20-bis-nor-prostanoic acid with antiulcer and anorectic activity, process for their preparation and pharmaceutical compositions thereof
NO974651L (no) Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
ATE63114T1 (de) Piperazinderivate, verfahren zu ihrer herstellung und diese als wirkstoffe enthaltende pharmazeutische zusammensetzungen.
ES8300747A1 (es) Procedimiento para la preparacion de derivados de acido in- dolacetico
ES512748A0 (es) "procedimiento para la preparacion de comprimidos a base del antibiotico fosfomicina".
SE8303012D0 (sv) Farmaceutisk komposition
BG60697B2 (en) Medicamentous form having continous release based on ethodolacquer
KR960007619A (ko) 신규 알긴산 유도체 및 그 제조방법

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8406081-3

Format of ref document f/p: F

NUG Patent has lapsed
NUG Patent has lapsed